Share on LinkedInShare on LinkedIn

ARTICLE · 04 JANUARY 2023

Parallel Importation Of Pharmaceuticals – When Is Repackaging Necessary?

Repackaging of pharmaceutical products by parallel importers is a long debated subject. The above question was reconsidered in a set of judgements by the CJEU in November this year...

United KingdomIntellectual Property

Repackaging of pharmaceutical products by parallel importers is a long debated subject. The above question was reconsidered in a set of judgements by the CJEU in November this year (Novartis Pharma GmbH v Abacus Medicine A/S (C 147/20), Bayer Intellectual Property GmbH v kohlpharma GmbH (C 204/20) and Merck Sharp & Dohme BV and others v Abacus Medicine A/S and others (C 147/20)) prompted by a new EU Regulation on the packaging of medicinal products.

New authenticating requirements

Since 2019, as a result of the implementation of a new EU Regulation, all medicinal products for human use in the EU are required to have two safety features:-

  1. a unique identifier (typically a barcode or QR code) that indicates the source of the goods, and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from